Document Detail


Comparison of the reintroduced MEIA assay with HPLC-MS/MS for the determination of whole-blood sirolimus from transplant recipients.
MedLine Citation:
PMID:  16628125     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Therapeutic monitoring with dosage individualization of sirolimus drug therapy is standard clinical practice for organ transplant recipients. For several years sirolimus monitoring has been restricted as a result of lack of an immunoassay. The recent reintroduction of the microparticle enzyme immunoassay (MEIA) for sirolimus on the IMx analyser has the potential to address this situation. This study, using patient samples, has compared the MEIA sirolimus method with an established HPLC-tandem mass spectrometry method (HPLC-MS/MS). An established HPLC-UV assay was used for independent cross-validation. For quality control materials (5, 11, 22 microg/L), the MEIA showed acceptable validation criteria based on intra- and inter-run precision (CV) and accuracy (bias) of <8% and <13%, respectively. The lower limit of quantitation was found to be approximately 3 microg/L. The performance of the immunoassay was compared with HPLC-MS/MS using EDTA whole-blood samples obtained from various types of organ transplant recipients (n = 116). The resultant Deming regression line was: MEIA =1.3 x HPLC-MS/MS + 1.3 (r = 0.967, S(y/x) = 1) with a mean bias of 49.2% +/- 23.1% (range, -2.4% to 128%; P<0.001). The reason for the large and variable bias was not explored in this study, but the sirolimus-metabolite cross-reactivity with the MEIA antibody could be a substantive contributing factor. Whereas the MEIA sirolimus method may be an adjunct to sirolimus dosage individualization in transplant recipients, users must consider the implications of the substantial and variable bias when interpreting results. In selected patients where difficult clinical issues arise, reference to a specific chromatographic method may be required.
Authors:
Raymond G Morris; Paul Salm; Paul J Taylor; Fiona A Wicks; Anastasia Theodossi
Related Documents :
1873305 - Measurement of the class iii antidysrhythmic drug, uk-68,798, in plasma by radioimmunoa...
10799465 - A latex bead-based flow cytometric immunoassay capable of simultaneous typing of multip...
8590935 - Biocompatible sample pretreatment for immunochemical techniques using micellar liquid c...
6414735 - Clinical evaluation of two direct procedures for free thyroxin, and of free thyroxin in...
18352125 - Separation of a binary fluid mixture in a porous horizontal cavity.
8678305 - Separation of mono- and divinyl chlorophyll species by high-performance liquid chromato...
Publication Detail:
Type:  Comparative Study; Evaluation Studies; Journal Article    
Journal Detail:
Title:  Therapeutic drug monitoring     Volume:  28     ISSN:  0163-4356     ISO Abbreviation:  Ther Drug Monit     Publication Date:  2006 Apr 
Date Detail:
Created Date:  2006-04-21     Completed Date:  2006-10-17     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7909660     Medline TA:  Ther Drug Monit     Country:  United States    
Other Details:
Languages:  eng     Pagination:  164-8     Citation Subset:  IM    
Affiliation:
Department of Cardiology and Clinical Pharmacology, The Queen Elizabeth Hospital, Woodville, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Chromatography, High Pressure Liquid / methods*
Dose-Response Relationship, Drug
Humans
Immunoenzyme Techniques / methods*
Immunosuppressive Agents / blood,  therapeutic use
Kidney Transplantation / immunology
Mass Spectrometry / methods*
Monitoring, Immunologic / methods
Particle Size
Reproducibility of Results
Sirolimus / blood*,  therapeutic use
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use.
Next Document:  An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab.